Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO Breast 2025 | REACH AUT: ribociclib plus endocrine therapy in HR+/HER2- breast cancer

Christian Singer • 12 May 2025
ESMO Breast 2025
Breast Cancer
REACH AUT

Christian Singer, MD, Medical University of Vienna, Vienna, Austria, discusses final results from the REACH AUT study (CLEE011AAT01), a real-world analysis evaluating first-line ribociclib plus endocrine therapy in patients with HR+/HER2- metastatic breast cancer. The combination showed clinically meaningful progression-free and overall survival benefits, consistent with findings from the MONALEESA trials. Safety was manageable, with no unexpected signals. The most frequent adverse event was neutropenia. This interview took place at the 2025 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress in Munich, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Christian Singer

Elucidating treatment options for TNBC based on HRD and BRCA status
0:51
Elucidating treatment options for TNBC based on HRD and BRCA status
Christian Singer • 2 Jun 2025
The future landscape of treatment intensification strategies for TNBC
0:39
The future landscape of treatment intensification strategies for TNBC
Christian Singer • 2 Jun 2025
Influential breast cancer trials at ASCO 2025: DESTINY-Breast09
0:38
Influential breast cancer trials at ASCO 2025: DESTINY-Breast09
Christian Singer • 2 Jun 2025
ABCSG 45: olaparib and carboplatin versus TAC in HRD-positive TNBC
0:52
ABCSG 45: olaparib and carboplatin versus TAC in HRD-positive TNBC
Christian Singer • 2 Jun 2025

Related Videos

CRCI and compromised adjuvant chemotherapy delivery in cancer
5:16
CRCI and compromised adjuvant chemotherapy delivery in cancer
Filippos Koinis • 1 Jun 2026
Phase I trial of neoadjuvant rintatolimod and celecoxib in resectable mCRC
1:20
Phase I trial of neoadjuvant rintatolimod and celecoxib in resectable mCRC
Sarbajit Mukherjee • 1 Jun 2026
ASCENT-04: PFS2 with sacituzumab govitecan and pembrolizumab in PD-L1+ mTNBC
1:12
ASCENT-04: PFS2 with sacituzumab govitecan and pembrolizumab in PD-L1+ mTNBC
Kevin Kalinsky • 31 May 2026
Clinical relevance of PFS2 in metastatic triple-negative breast cancer
1:10
Clinical relevance of PFS2 in metastatic triple-negative breast cancer
Kevin Kalinsky • 31 May 2026
The content of VJOncology is intended for healthcare professionals